Prosight Management, LP Adc Therapeutics Sa Transaction History

Prosight Management, LP

$378 Million
Q3 2025

A detailed history of Prosight Management, LP transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Prosight Management, LP holds 7,472,303 shares of ADCT stock, worth $29.6 Million. This represents 7.9% of its overall portfolio holdings.

Number of Shares

7,472,303

Previous 10,467,771 28.62%

Holding current value

$29.6 Million

Previous $28.1 Million 6.54%

% of portfolio

7.9%

Previous 7.6%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$2.64 - $4.02 $7.91 Million - $12 Million	-2,995,468 Reduced 28.62%	7,472,303 $29.9 Million
Q2 2025 Aug 14, 2025	BUY	$1.1 - $3.67 $1.02 Million - $3.39 Million	924,767 Added 9.69%	10,467,771 $28.1 Million
Q1 2025 May 15, 2025	BUY	$1.39 - $2.02 $38,925 - $56,568	28,004 Added 0.29%	9,543,004 $13.5 Million
Q4 2024 Feb 14, 2025	SELL	$1.89 - $3.48 $229,137 - $421,904	-121,237 Reduced 1.26%	9,515,000 $18.9 Million
Q3 2024 Nov 14, 2024	BUY	$2.59 - $4.01 $171,553 - $265,610	66,237 Added 0.69%	9,636,237 $30.4 Million
Q2 2024 Aug 14, 2024	BUY	$2.55 - $5.09 $6.43 Million - $12.8 Million	2,519,700 Added 35.74%	9,570,000 $30.2 Million
Q1 2024 May 15, 2024	BUY	$1.66 - $5.29 $960,310 - $3.06 Million	578,500 Added 8.94%	7,050,300 $31.7 Million
Q4 2023 Feb 14, 2024	BUY	$0.47 - $1.79 $502,786 - $1.91 Million	1,069,759 Added 19.8%	6,471,800 $10.7 Million
Q3 2023 Nov 14, 2023	SELL	$0.72 - $2.37 $130,938 - $431,005	-181,859 Reduced 3.26%	5,402,041 $4.86 Million
Q2 2023 Aug 14, 2023	BUY	$1.9 - $2.66 $4.42 Million - $6.19 Million	2,326,540 Added 71.42%	5,583,900 $12 Million
Q1 2023 May 12, 2023	BUY	$1.92 - $5.45 $5.36 Million - $15.2 Million	2,794,050 Added 603.06%	3,257,360 $6.35 Million
Q4 2022 Feb 14, 2023	BUY	$2.87 - $5.24 $619,001 - $1.13 Million	215,680 Added 87.1%	463,310 $1.78 Million
Q3 2022 Nov 14, 2022	BUY	$4.66 - $10.31 $1.15 Million - $2.55 Million	247,630 New	247,630 $1.19 Million

Others Institutions Holding ADCT

# of Institutions

107

Shares Held

67.3M

Call Options Held

39.8K

Put Options Held

68.4K

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $307M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Prosight Management, LP with notifications on news.

Account

Prosight Management, LP Adc Therapeutics Sa Transaction History